What does positron emission tomography offer oncology?

被引：19

作者：

Anderson, H ^{[1
]}

Price, P ^{[1
]}

机构：

[1] Hammersmith Hosp, Imperial Coll, Sch Med, MRC Cyclotron Unit,CRC PET Oncol Grp, London W12 0NN, England

来源：

EUROPEAN JOURNAL OF CANCER | 2000年 / 36卷 / 16期

关键词：

positron emission tomography; radionuclides; F-18]-FDG;

D O I：

10.1016/S0959-8049(00)00292-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The origins of positron emission tomography (PET) dare back 70 years. Since the 1970s, however, its use has increased exponentially in the fields of neurology, cardiology and oncology. [F-18]-Fluorodeoxyglucose (FDG) whole-body scanning is by far the most widely utilised and recognised application of PET in oncology. However, PET is a very versatile and powerful imaging modality capable of helping bridge the gap between the laboratory and the clinic. This article reviews the history and current applications of PET in oncology and then explores some of the newer applications and potential future uses of this versatile technology particularly in the area of cancer research. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：2028 / 2035

页数：8

共 92 条

[61] Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography [J].